CSI Market
Sign In | Register

Fulcrum Therapeutics Inc (FULC) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access FULC Annual Income Statement →
The data below summarizes Fulcrum Therapeutics Inc's income statement results from Mar 31 2025 to Mar 31 2026, enabling period-by-period comparison of operating performance.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Mar 31 2026)
Q1 2026 		(Dec 31 2025) (Sep 30 2025) (Jun 30 2025) (Mar 31 2025)
Revenues
Total Revenue0.00
Costs & Expenses
Gross Profit0.00
Selling, Administration, Marketing8.10
Depreciation & Amortization0.34
Research and Development Expense14.08
Total operating costs including COS22.19
Operating income / -loss-22.19
Interest Expense3.30
Net Interest Expense / -Income3.30
Other loss / -income-6.59
Total costs & expenses18.89
Income & Taxes
Income / -loss before income taxes-18.89
Income after income taxes-18.89
Income / -loss from continuing operations-18.89
Net income / -loss-18.89
Income / -loss to shareholder-18.89
EBIT-15.60
EBITD-15.26
EBITDA-15.26
Earnings Per Share
Basic EPS (excl. extra items)-0.25
Basic Net EPS-0.25
Basic shares outstanding (Mill. of Units)76.22
Diluted Net EPS-0.25
Diluted average shares (Mill. of Units)76.22
4 historic quarters locked

Sign in to unlock the full Fulcrum Therapeutics Inc income statement history.

Sign In Create Free Account

About Fulcrum Therapeutics Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: July 30, 2026
  • Original filing: fulc-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.